Tever O, Mentrup T, Chinn I, Ishikuma H, Fluhrer R, Schmitz M
Cell Mol Life Sci. 2025; 82(1):107.
PMID: 40072623
PMC: 11904002.
DOI: 10.1007/s00018-025-05645-5.
Rubin T, Bernier S, Hoon Lim L, Salman M, Leung E, Mhanni A
Front Immunol. 2025; 16:1557632.
PMID: 40061936
PMC: 11885508.
DOI: 10.3389/fimmu.2025.1557632.
Mentani A, Maresca M, Shiriaeva A
Cells. 2025; 14(4).
PMID: 39996750
PMC: 11853414.
DOI: 10.3390/cells14040277.
Belot A, Tusseau M, Cognard J, Georgin-Lavialle S, Boursier G, Hedrich C
ACR Open Rheumatol. 2025; 7(2):e70003.
PMID: 39964335
PMC: 11834591.
DOI: 10.1002/acr2.70003.
Ye J, Fu J, Hou H, Wang Y, Deng W, Hao S
Life Med. 2025; 2(3):lnad021.
PMID: 39872301
PMC: 11749111.
DOI: 10.1093/lifemedi/lnad021.
The TLR7/9 adaptors TASL and TASL2 mediate IRF5-dependent antiviral responses and autoimmunity in mouse.
Drobek A, Bernaleau L, Delacretaz M, Calderon Copete S, Royer-Chardon C, Longepierre M
Nat Commun. 2025; 16(1):967.
PMID: 39856058
PMC: 11759703.
DOI: 10.1038/s41467-024-55692-y.
Opportunities and limitations of B cell depletion approaches in SLE.
Stockfelt M, Teng Y, Vital E
Nat Rev Rheumatol. 2025; 21(2):111-126.
PMID: 39815102
DOI: 10.1038/s41584-024-01210-9.
To cleave or not and how? The DNA exonucleases and endonucleases in immunity.
Lu M, Wu J, Gao Q, Jin R, An C, Ma T
Genes Dis. 2025; 12(2):101219.
PMID: 39759116
PMC: 11697192.
DOI: 10.1016/j.gendis.2024.101219.
Discovery of Potent and Orally Bioavailable Pyrimidine Amide cGAS Inhibitors via Structure-Guided Hybridization.
Cyr P, Fader L, Burch J, Pike K, Sietsema D, Boily M
ACS Med Chem Lett. 2024; 15(12):2201-2209.
PMID: 39691514
PMC: 11647726.
DOI: 10.1021/acsmedchemlett.4c00471.
Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus.
Goldbach-Mansky R, Alehashemi S, de Jesus A
Nat Rev Rheumatol. 2024; 21(1):22-45.
PMID: 39623155
DOI: 10.1038/s41584-024-01184-8.
ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis.
Guillet S, Lazarov T, Jordan N, Boisson B, Tello M, Craddock B
Elife. 2024; 13.
PMID: 39570652
PMC: 11581429.
DOI: 10.7554/eLife.96085.
The prototypical interferonopathy: Aicardi-Goutières syndrome from bedside to bench.
Hofer M, Modesti N, Coufal N, Wang Q, Sase S, Miner J
Immunol Rev. 2024; 327(1):83-99.
PMID: 39473130
PMC: 11672868.
DOI: 10.1111/imr.13413.
Monogenic lupus - from gene to targeted therapy.
Menzel K, Novotna K, Jeyakumar N, Wolf C, Lee-Kirsch M
Mol Cell Pediatr. 2024; 11(1):8.
PMID: 39264482
PMC: 11393215.
DOI: 10.1186/s40348-024-00181-x.
Protein-protein interactions in cGAS-STING pathway: a medicinal chemistry perspective.
Zhang S, Li H, Zhou Y, Liu X, Li D, Hao C
Future Med Chem. 2024; 16(17):1801-1820.
PMID: 39263789
PMC: 11457635.
DOI: 10.1080/17568919.2024.2383164.
cGAS activation in classical dendritic cells causes autoimmunity in TREX1-deficient mice.
Li T, Yum S, Wu J, Li M, Deng Y, Sun L
Proc Natl Acad Sci U S A. 2024; 121(38):e2411747121.
PMID: 39254994
PMC: 11420187.
DOI: 10.1073/pnas.2411747121.
Systemic lupus erythematosus genetics: insights into pathogenesis and implications for therapy.
Ghodke-Puranik Y, Olferiev M, Crow M
Nat Rev Rheumatol. 2024; 20(10):635-648.
PMID: 39232240
DOI: 10.1038/s41584-024-01152-2.
A novel TREX1 inhibitor, VB-85680, upregulates cellular interferon responses.
Flowers S, Petronella B, McQueney M, Fanelli B, Eisenberg W, Uveges A
PLoS One. 2024; 19(8):e0305962.
PMID: 39178223
PMC: 11343403.
DOI: 10.1371/journal.pone.0305962.
Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer.
Murayama T, Mahadevan N, Meador C, Ivanova E, Pan Y, Knelson E
Cancer Res Commun. 2024; 4(9):2399-2414.
PMID: 39177280
PMC: 11391691.
DOI: 10.1158/2767-9764.CRC-24-0360.
Global research trends in precision-targeted therapies for systemic lupus erythematosus (2003-2023): A bibliographic study.
Yuan Z, Zhang W, Jin Z, Wang Y, Lin Z, Xie Z
Heliyon. 2024; 10(13):e33350.
PMID: 39050478
PMC: 11268211.
DOI: 10.1016/j.heliyon.2024.e33350.
PELI2 is a negative regulator of STING signaling that is dynamically repressed during viral infection.
Ritchie C, Li L
Mol Cell. 2024; 84(13):2423-2435.e5.
PMID: 38917796
PMC: 11246219.
DOI: 10.1016/j.molcel.2024.06.001.